Joseph McKendrick
Overview
Explore the profile of Joseph McKendrick including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
1163
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Harrop S, Casan J, Rose H, Sullivan M, Mehr S, Ngu H, et al.
Br J Haematol
. 2025 Mar;
PMID: 40031954
Germline homozygous loss-of-function mutations in TET2 result in significant childhood immunodeficiency that resembles autoimmune lymphoproliferative syndrome and predisposes one to lymphoma. The implications of heterozygous variants are less well understood....
2.
Manos K, Chong G, Keane C, Lee S, Smith C, Churilov L, et al.
Leukemia
. 2023 Mar;
37(5):1092-1102.
PMID: 36906715
Immune evasion, due to abnormal expression of programmed-death ligands 1 and 2 (PD-L1/PD-L2), predicts poor outcomes with chemoimmunotherapy in diffuse large B-cell lymphoma (DLBCL). Immune checkpoint inhibition (ICI) has limited...
3.
Ng S, Chu J, Chander S, Bressel M, McKendrick J, Wong R, et al.
Radiother Oncol
. 2020 Oct;
155:27-32.
PMID: 33065186
Background And Purpose: The chemotherapy exposure during chemoradiotherapy for rectal cancer is adequate for radiosensitization but suboptimal for treatment of distant micrometastasis. This study aimed to determine tolerability, dose intensity,...
4.
Tie J, Cohen J, Wang Y, Christie M, Simons K, Lee M, et al.
JAMA Oncol
. 2019 Oct;
5(12):1710-1717.
PMID: 31621801
Importance: Adjuvant chemotherapy in patients with stage III colon cancer prevents recurrence by eradicating minimal residual disease. However, which patients remain at high risk of recurrence after completing standard adjuvant...
5.
Delahunty R, Lee M, Wong H, Johns J, McKendrick J, Lee B, et al.
Intern Med J
. 2019 Mar;
50(2):165-172.
PMID: 30887616
Background: In the treatment of metastatic colorectal cancer (mCRC), exposure to all three active cytotoxic agents, 5-fluorouracil/capecitabine, irinotecan and oxaliplatin, improves overall survival. The addition of biologic agents (bevacizumab and...
6.
Neeman J, Friedman A, McKendrick J
Leuk Lymphoma
. 2019 Mar;
60(9):2283-2286.
PMID: 30822188
A 67-year-old man with an 11-year history of composite lymphoma was admitted with fevers in the context of neutropenia and acute liver injury, 4 months after the commencement of single-agent...
7.
Soon J, Anton A, Torres J, Lawrence R, Parente P, McKendrick J, et al.
Support Care Cancer
. 2018 Oct;
27(2):373-382.
PMID: 30350189
Purpose: Testicular seminomas occur in young men and are highly curable. Toxicities following treatment for men with extensive stage II-III seminomas may cause long-term morbidities. However, it is not clear...
8.
Aung S, Parente P, McKendrick J
World J Oncol
. 2017 Nov;
5(3):149-152.
PMID: 29147395
Adrenocortical carcinomas (ACCs) are rare and often aggressive with more than 50% of the cases already in stage III-IV (ENSAT) at the time of diagnosis. Nearly 60% of ACCs present...
9.
Tamjid B, McKendrick J, Schwarer A, Doig R, James P, Hosking P, et al.
Asia Pac J Clin Oncol
. 2016 Dec;
13(3):226-233.
PMID: 28004881
Aim: Relapsed/refractory (R/R) aggressive lymphoma outcomes are poor. There is no standard treatment. PACEBOM (prednisolone, doxorubicin, cyclophosphamide, etoposide, bleomycin, vincristine and methotrexate) has shown efficacy for several lymphoma subtypes in...
10.
Wong K, Lee M, Davis I, Parente P, McKendrick J, Pezaro C
Asia Pac J Clin Oncol
. 2016 Oct;
13(5):e534-e536.
PMID: 27726296
Posterior reversible encephalopathy syndrome (PRES) has been described in the context of uncontrolled hypertension, eclampsia, renal disease and autoimmune conditions, or in patients treated with chemotherapy or immunosuppressive agents. In...